NASDAQ:ALNY - Alnylam Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$99.98 +1.01 (+1.02 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$99.98
Today's Range$98.82 - $100.54
52-Week Range$62.96 - $153.99
Volume530,720 shs
Average Volume980,403 shs
Market Capitalization$9.95 billion
P/E Ratio-18.45
Dividend YieldN/A
Beta2.73

About Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals logoAlnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ALNY
CUSIP02043Q10
Phone617-551-8200

Debt

Debt-to-Equity Ratio0.02
Current Ratio14.61
Quick Ratio14.61

Price-To-Earnings

Trailing P/E Ratio-18.45
Forward P/E Ratio-14.92
P/E GrowthN/A

Sales & Book Value

Annual Sales$89.91 million
Price / Sales111.78
Cash FlowN/A
Price / CashN/A
Book Value$17.46 per share
Price / Book5.73

Profitability

EPS (Most Recent Fiscal Year)($5.42)
Net Income$-490,870,000.00
Net Margins-565.20%
Return on Equity-36.81%
Return on Assets-31.28%

Miscellaneous

Employees749
Outstanding Shares100,520,000

Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) issued its earnings results on Thursday, May, 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, beating analysts' consensus estimates of ($1.47) by $0.06. The biopharmaceutical company had revenue of $21.90 million for the quarter, compared to the consensus estimate of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business's quarterly revenue was up 15.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.25) earnings per share. View Alnylam Pharmaceuticals' Earnings History.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Alnylam Pharmaceuticals.

What price target have analysts set for ALNY?

21 brokers have issued twelve-month target prices for Alnylam Pharmaceuticals' stock. Their predictions range from $56.00 to $207.00. On average, they anticipate Alnylam Pharmaceuticals' stock price to reach $138.6667 in the next twelve months. View Analyst Ratings for Alnylam Pharmaceuticals.

What are Wall Street analysts saying about Alnylam Pharmaceuticals stock?

Here are some recent quotes from research analysts about Alnylam Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Alnylam posted wider than expected loss and missed revenue estimates in the first quarter of 2018. The company reported positive data from the ATLAS study which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020. Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company." (5/10/2018)
  • 2. Chardan Capital analysts commented, "We now raise our PT to $175, after: (1) increasing the patisiran probability of success to 97%, and (2) lowering the Alnylam WACC to 8% to reflect further RNAi therapeutics platform de-risking. We now update our Alnylam patient-based and other models to reflect recent positives, while consolidating views from recent Chardan macro research (e.g. on novel lipid-lowering therapies). (See Figures 3-7.) Notably, a near- best-case safety and efficacy profile emerged from the pivotal APOLLO trial (as discussed in our 20 September 2017 research); and, Alnylam proceeded to file patisiran in an expeditious fashion. We thus newly model a 97% probability of success (POS) for patisiran and $1.77 billion in 2030E risk-adjusted franchise sales (patisiran and follow ons). We now increase the POS of givosiran, to 80% ($540 million in 2030E sales) from 40% in our previous model, given the product’s progress ahead of our expectations." (1/19/2018)
  • 3. FBR & Co analysts commented, "We are initiating coverage of Alnylam Pharmaceuticals, Inc. (ALNY), making it our Alpha Generator pick, with a Buy rating and a 12-month price target of $150 per share, due to our utmost conviction that Alnylam represents a foundational biopharma investment, led by the firm’s hereditary transthyretin amyloidosis (hATTR) franchise." (10/30/2017)
  • 4. Needham & Company LLC analysts commented, "Alnylam announced today that dosing of fitusiran, in development for Hemophilia, has been suspended in all clinical trials. A patient death tied to a thrombotic event was reported in ongoing Phase 2 OLE trial and FDA has issued a clinical hold. Alnylam had just initiated a Phase 3 program in Jul 2017. The incident raises questions around safety margin for the drug. Fitusiran is intended to increase thrombin levels closer to normal range. Concerns, however, have been raised around risk of thrombosis if thrombin levels are too high, particularly when used w/ on-demand factor or bypassing agents. Based on available clinical data, we believe fitusiran allows for better control of Hemophilia, but patients and physicians may have a narrower safety window when managing bleeds. Our bias is Alnylam and FDA will reach agreement on a protocol to more closely monitor patients and that clinical development will resume over next 3-6 months. We continue to believe in long-term value of RNAi, but acknowledge greater risk than we anticipated around fitusiran. We have reduced our fitusiran estimates to reflect delayed launch and slower market penetration." (9/7/2017)

Who are some of Alnylam Pharmaceuticals' key competitors?

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the folowing people:
  • Michael W. Bonney, Independent Chairman of the Board (Age 58)
  • Barry E. Greene, President (Age 53)
  • John M. Maraganore Ph.D., Chief Executive Officer, Director (Age 54)
  • Manmeet S. Soni, Chief Financial Officer, Senior Vice President, Principal Financial Officer (Age 39)
  • Yvonne L. Greenstreet M.D., Chief Operating Officer, Executive Vice President (Age 54)
  • Akshay K. Vaishnaw M.D., Ph.D., Executive Vice President - Research and Development (Age 54)
  • Laurie B. Keating, Senior Vice President, General Counsel, Secretary (Age 62)
  • Pushkal Garg M.D., Senior Vice President - Clinical Development, Chief Medical Officer
  • Theresa Heggie, Senior Vice President, Head of Europe and Canada (Age 57)
  • Peter F. Smith Ph.D., Senior Vice President - Early Development (Age 59)

Has Alnylam Pharmaceuticals been receiving favorable news coverage?

News headlines about ALNY stock have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a coverage optimism score of 0.22 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 48.29 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.14%), Baillie Gifford & Co. (3.81%), BB Biotech AG (1.01%), Point72 Asset Management L.P. (0.90%), Artal Group S.A. (0.60%) and Northern Trust Corp (0.47%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, David E I Pyott, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp, Sanofi and Yvonne Greenstreet. View Institutional Ownership Trends for Alnylam Pharmaceuticals.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Slate Path Capital LP, Artal Group S.A., Swiss National Bank, BB Biotech AG, Opus Point Partners Management LLC, Eventide Asset Management LLC and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Barry E Greene, Dennis A Ausiello, John Maraganore, Laurie Keating, Michael Mason, Paul Schimmel, Philip A Sharp and Yvonne Greenstreet. View Insider Buying and Selling for Alnylam Pharmaceuticals.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Farallon Capital Management LLC, Rockefeller Capital Management L.P., Legal & General Group Plc, Baillie Gifford & Co., Green Valley Investors LLC, Eversept Partners LLC and Franklin Resources Inc.. Company insiders that have bought Alnylam Pharmaceuticals stock in the last two years include David E I Pyott, Laurie Keating and Sanofi. View Insider Buying and Selling for Alnylam Pharmaceuticals.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $99.98.

How big of a company is Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals has a market capitalization of $9.95 billion and generates $89.91 million in revenue each year. The biopharmaceutical company earns $-490,870,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis. Alnylam Pharmaceuticals employs 749 workers across the globe.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 300 THIRD STREET, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-551-8200 or via email at [email protected]


MarketBeat Community Rating for Alnylam Pharmaceuticals (ALNY)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  742 (Vote Outperform)
Underperform Votes:  298 (Vote Underperform)
Total Votes:  1,040
MarketBeat's community ratings are surveys of what our community members think about Alnylam Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Alnylam Pharmaceuticals in the last 12 months. Their average twelve-month price target is $138.6667, suggesting that the stock has a possible upside of 38.69%. The high price target for ALNY is $207.00 and the low price target for ALNY is $56.00. There are currently 3 sell ratings, 3 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.622.622.592.55
Ratings Breakdown: 3 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
3 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
4 Hold Rating(s)
14 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
4 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $138.6667$139.3333$131.2381$125.8571
Price Target Upside: 38.69% upside37.71% upside7.80% upside0.41% downside

Alnylam Pharmaceuticals (NASDAQ:ALNY) Consensus Price Target History

Price Target History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$118.00MediumView Rating Details
5/4/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$160.00 ➝ $134.00N/AView Rating Details
5/4/2018Stifel NicolausLower Price TargetHold ➝ Hold$107.00 ➝ $95.00HighView Rating Details
4/2/2018B. RileyReiterated RatingBuy$200.00MediumView Rating Details
4/2/2018Jefferies GroupReiterated RatingBuyHighView Rating Details
3/28/2018Evercore ISIInitiated CoverageIn ➝ line$131.18 ➝ $143.00MediumView Rating Details
3/26/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$169.00 ➝ $207.00LowView Rating Details
3/13/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$151.00 ➝ $154.00HighView Rating Details
2/9/2018NomuraBoost Price TargetSell$86.00LowView Rating Details
1/25/2018Leerink SwannBoost Price TargetMarket Perform ➝ Market Perform$132.00 ➝ $135.00LowView Rating Details
1/19/2018Chardan CapitalReiterated RatingBuyLowView Rating Details
1/7/2018Piper Jaffray CompaniesReiterated RatingBuy$182.00MediumView Rating Details
12/15/2017Goldman Sachs GroupUpgradeBuy ➝ Conviction-BuyHighView Rating Details
11/9/2017CowenReiterated RatingBuy$151.00N/AView Rating Details
11/9/2017JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/AView Rating Details
11/8/2017BarclaysBoost Price TargetOverweight$127.00 ➝ $158.00N/AView Rating Details
11/3/2017Needham & Company LLCReiterated RatingBuy ➝ Buy$125.00 ➝ $152.00N/AView Rating Details
10/30/2017FBR & CoInitiated CoverageBuy ➝ Buy$150.00N/AView Rating Details
9/21/2017Ladenburg ThalmannReiterated RatingBuy$90.00 ➝ $146.00LowView Rating Details
9/21/2017Sanford C. BernsteinReiterated RatingOutperform ➝ Buy$94.00 ➝ $135.00LowView Rating Details
9/15/2017InstinetInitiated CoverageReduce ➝ Reduce$56.00LowView Rating Details
6/2/2017Janney Montgomery ScottInitiated CoverageUnderperform ➝ Sell$69.70 ➝ $67.00LowView Rating Details
3/29/2017UBSInitiated CoverageNeutral ➝ Neutral$55.00N/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings History and Estimates Chart

Earnings by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) Earnings Estimates

2018 EPS Consensus Estimate: ($4.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($1.44)($1.25)($1.35)
Q2 20183($1.64)($1.46)($1.54)
Q3 20183($1.56)($0.69)($1.13)
Q4 20183($1.46)($0.14)($0.93)

Alnylam Pharmaceuticals (NASDAQ ALNY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($1.76)N/AView Earnings Details
5/3/2018Q1 2018($1.47)($1.41)$35.23 million$21.90 millionViewN/AView Earnings Details
2/8/2018Q4 2017($1.38)($1.48)$19.31 million$37.90 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.23)($1.34)$28.15 million$17.10 millionViewN/AView Earnings Details
8/9/2017Q2 2017($1.22)($1.34)$23.86 million$15.93 millionViewListenView Earnings Details
5/5/2017Q1 2017($1.22)($1.25)$22.91 million$19.00 millionViewN/AView Earnings Details
2/8/2017Q416($1.34)($1.32)$10.66 million$17.50 millionViewListenView Earnings Details
11/2/2016Q316($1.14)($1.21)$9.14 million$13.70 millionViewN/AView Earnings Details
8/4/2016Q216($1.24)($1.05)$8.09 million$8.70 millionViewListenView Earnings Details
5/2/2016Q116($1.05)($1.21)$7.79 million$7.30 millionViewListenView Earnings Details
2/11/2016Q415($0.96)($1.07)$9.59 million$7.60 millionViewListenView Earnings Details
11/9/2015Q315($0.91)($0.91)$7.55 million$6.30 millionViewN/AView Earnings Details
8/6/2015Q215($0.75)($0.85)$12.64 million$8.69 millionViewN/AView Earnings Details
5/7/2015Q115($0.65)($0.62)$15.40 million$18.51 millionViewN/AView Earnings Details
2/12/2015Q414($0.66)($0.28)$13.10 million$24.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.63)($0.58)$8.93 million$11.00 millionViewN/AView Earnings Details
8/7/2014Q214($0.54)($0.63)$9.36 million$7.30 millionViewN/AView Earnings Details
5/8/2014Q114($1.18)($0.39)$10.80 million$8.30 millionViewN/AView Earnings Details
2/19/2014Q413($0.45)($0.51)$9.98 million$10.80 millionViewN/AView Earnings Details
11/6/2013Q313($0.39)($0.48)$8.64 million$9.00 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.35)($0.29)$8.99 million$8.70 millionViewListenView Earnings Details
5/6/2013Q1 2013($0.29)($0.15)$15.56 million$18.60 millionViewListenView Earnings Details
2/7/2013Q4 2012($1.45)($1.20)$15.82 million$8.50 millionViewListenView Earnings Details
11/5/2012Q312($0.32)($0.31)$17.30 million$16.80 millionViewN/AView Earnings Details
8/6/2012($0.21)($0.25)ViewN/AView Earnings Details
5/3/2012($0.35)($0.25)ViewN/AView Earnings Details
2/9/2012($0.33)($0.33)ViewN/AView Earnings Details
11/1/2011($0.35)($0.31)ViewN/AView Earnings Details
8/1/2011($0.36)($0.33)ViewN/AView Earnings Details
5/2/2011($0.30)($0.38)ViewN/AView Earnings Details
2/17/2011($0.35)($0.16)ViewN/AView Earnings Details
11/3/2010Q3 2010($0.39)($0.23)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.30)($0.35)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.30)($0.29)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.30)($0.19)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.24)($0.22)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.29)($0.55)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.24)($0.19)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.15)($0.23)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.21)($0.07)ViewN/AView Earnings Details
8/6/2008Q2 2008($0.09)($0.31)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.14)($0.03)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.22)$0.04ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Alnylam Pharmaceuticals (NASDAQ:ALNY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 90.56%
Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ ALNY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2018Yvonne GreenstreetCOOSell7,221$136.54$985,955.347,221View SEC Filing  
3/20/2018Laurie KeatingSVPSell1,562$149.83$234,034.4616,062View SEC Filing  
3/14/2018Akshay VaishnawInsiderSell88,554$143.10$12,672,077.4055,856View SEC Filing  
3/14/2018Barry E GreenePresidentSell38,460$143.10$5,503,626.0097,544View SEC Filing  
3/13/2018Laurie KeatingSVPSell20,000$145.00$2,900,000.0024,500View SEC Filing  
3/13/2018Paul SchimmelDirectorSell27,823$150.00$4,173,450.0010,000View SEC Filing  
3/9/2018Philip A SharpDirectorSell15,000$129.00$1,935,000.00155,795View SEC Filing  
1/4/2018Michael MasonVPSell36,745$131.59$4,835,274.556,352View SEC Filing  
12/20/2017Laurie KeatingSVPSell6,249$121.20$757,378.8017,749View SEC Filing  
12/1/2017Laurie KeatingSVPSell30,000$135.89$4,076,700.0041,500View SEC Filing  
11/22/2017John MaraganoreCEOSell73,415$130.90$9,610,023.50223,125View SEC Filing  
11/15/2017John MaraganoreCEOSell74,000$126.86$9,387,640.00223,710View SEC Filing  
11/2/2017Dennis A AusielloDirectorSell20,000$130.00$2,600,000.0020,000View SEC Filing  
10/30/2017Akshay VaishnawEVPSell33,666$121.46$4,089,072.3645,201View SEC Filing  
10/2/2017Barry E GreenePresidentSell85,316$125.00$10,664,500.00View SEC Filing  
9/20/2017Barry E GreenePresidentSell76,815$100.00$7,681,500.00165,399View SEC Filing  
5/31/2017SanofiMajor ShareholderBuy297,501$71.87$21,381,396.87View SEC Filing  
5/30/2017Laurie KeatingSVPBuy11,500$65.35$751,525.0011,500View SEC Filing  
5/23/2017Akshay VaishnawEVPSell11,000$75.00$825,000.0021,297View SEC Filing  
5/16/2017Michael MasonVPSell9,375$70.00$656,250.005,625View SEC Filing  
5/15/2017Akshay VaishnawSVPSell43,750$65.00$2,843,750.0043,047View SEC Filing  
1/25/2017Philip A SharpDirectorSell15,000$37.95$569,250.00155,795View SEC Filing  
1/18/2017Philip A SharpDirectorSell15,000$37.83$567,450.00155,795View SEC Filing  
11/30/2016Akshay VaishnawCMOSell29,165$44.99$1,312,133.3534,915View SEC Filing  
10/13/2016David E I PyottDirectorBuy27,900$37.00$1,032,300.00View SEC Filing  
7/20/2016John MaraganoreCEOSell30,151$64.69$1,950,468.19148,465View SEC Filing  
4/20/2016John MaraganoreCEOSell30,151$67.46$2,033,986.46148,465View SEC Filing  
3/9/2016Michael W BonneyDirectorBuy2,000$58.36$116,720.00View SEC Filing  
2/22/2016David-Alexandre C GrosSVPBuy1,000$62.75$62,750.00100View SEC Filing  
2/1/2016SanofiMajor ShareholderBuy205,030$69.75$14,300,842.50View SEC Filing  
1/20/2016John MaraganoreCEOSell30,152$71.78$2,164,310.56133,389View SEC Filing  
12/4/2015Philip A. SharpDirectorSell30,000$109.00$3,270,000.00140,795View SEC Filing  
12/2/2015John MaraganoreCEOSell58,689$104.87$6,154,715.43133,389View SEC Filing  
11/20/2015John MaraganoreCEOSell58,690$102.88$6,038,027.20133,389View SEC Filing  
11/12/2015Kevin P. StarrDirectorSell75,000$103.89$7,791,750.00View SEC Filing  
6/16/2015Akshay VaishnawCMOSell8,750$128.83$1,127,262.50View SEC Filing  
5/12/2015Michael W BonneyDirectorBuy2,000$112.16$224,320.00View SEC Filing  
4/21/2015Paul SchimmelDirectorSell10,000$130.02$1,300,200.00View SEC Filing  
3/19/2015Dennis A AusielloDirectorSell5,000$120.00$600,000.00View SEC Filing  
3/17/2015Akshay VaishnawCMOSell8,750$116.86$1,022,525.00View SEC Filing  
1/29/2015SanofiMajor ShareholderBuy97,118$95.00$9,226,210.00View SEC Filing  
1/26/2015John MaraganoreCEOBuy10,000$95.00$950,000.00View SEC Filing  
1/26/2015Steven M PaulDirectorBuy1,000$95.00$95,000.00View SEC Filing  
12/19/2014Barry E GreeneCOOSell11,200$100.00$1,120,000.00View SEC Filing  
12/16/2014Akshay VaishnawEVPSell10,626$93.60$994,593.60View SEC Filing  
12/15/2014Michael MasonVPSell22,162$97.50$2,160,795.00View SEC Filing  
11/18/2014Laurence ReidSVPSell10,000$90.67$906,700.00View SEC Filing  
11/17/2014Barry E GreeneCOOSell33,200$89.63$2,975,716.00View SEC Filing  
10/28/2014Paul SchimmelDirectorSell15,000$95.00$1,425,000.00View SEC Filing  
10/22/2014Dennis A AusielloDirectorSell5,000$90.00$450,000.00View SEC Filing  
10/13/2014Philip A SharpDirectorSell110,000$85.00$9,350,000.00View SEC Filing  
9/25/2014Kevin P StarrDirectorSell90,000$78.09$7,028,100.00View SEC Filing  
9/24/2014Kevin P StarrDirectorSell45,000$79.08$3,558,600.00View SEC Filing  
9/18/2014John MaraganoreCEOSell113,668$77.71$8,833,140.28View SEC Filing  
9/16/2014Akshay VaishnawEVPSell10,625$72.04$765,425.00View SEC Filing  
8/18/2014Laurence ReidSVPSell13,500$67.34$909,090.00View SEC Filing  
6/26/2014John MaraganoreCEOSell113,668$65.45$7,439,570.60View SEC Filing  
6/17/2014Akshay VaishnawEVPSell10,625$69.82$741,837.50View SEC Filing  
5/21/2014John ClarkeDirectorSell35,000$53.80$1,883,000.00View SEC Filing  
5/19/2014Laurence ReidSVPSell13,500$57.83$780,705.003,905View SEC Filing  
5/15/2014John MaraganoreCEOSell113,668$56.73$6,448,385.64106,320View SEC Filing  
3/25/2014Sanofimajor shareholderBuy344,448$66.88$23,036,682.24View SEC Filing  
3/18/2014Akshay VaishnawEVPSell32,769$73.95$2,423,267.55View SEC Filing  
2/19/2014Laurence ReidSVPSell20,400$80.06$1,633,224.003,905View SEC Filing  
1/24/2014Akshay VaishnawEVPSell7,890$85.75$676,567.50View SEC Filing  
1/13/2014Paul SchimmelDirectorSell15,000$85.36$1,280,400.00View SEC Filing  
12/20/2013Paul SchimmelDirectorSell15,000$65.00$975,000.00View SEC Filing  
12/17/2013Akshay VaishnawEVPSell33,480$60.72$2,032,905.6012,588View SEC Filing  
10/22/2013Paul SchimmelDirectorSell15,000$60.00$900,000.00View SEC Filing  
9/11/2013John MaraganoreCEOSell58,947$55.50$3,271,558.50View SEC Filing  
9/10/2013Akshay VaishnawEVPSell6,250$57.48$359,250.00View SEC Filing  
8/14/2013John MaraganoreCEOSell60,000$48.97$2,938,200.0018,617View SEC Filing  
7/12/2013Michael MasonVPSell14,200$50.00$710,000.00View SEC Filing  
7/10/2013John MaraganoreCEOSell60,000$37.11$2,226,600.00View SEC Filing  
7/1/2013Michael MasonVPSell27,000$32.00$864,000.00View SEC Filing  
6/17/2013Michael MasonVPSell23,625$29.93$707,096.25View SEC Filing  
6/11/2013Akshay VaishnawEVPSell15,000$31.08$466,200.00View SEC Filing  
5/28/2013Barry E GreeneCOOSell22,822$30.00$684,660.00View SEC Filing  
5/28/2013Laurence ReidSVPSell5,000$30.00$150,000.00View SEC Filing  
3/26/2013Kevin P StarrDirectorSell52,631$23.49$1,236,302.19View SEC Filing  
1/22/2013Philip A SharpDirectorBuy4,967$20.13$99,985.71View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alnylam Pharmaceuticals (NASDAQ ALNY) News Headlines

Source:
DateHeadline
Analyst Views on the Upside Potential of Alnylam PharmaceuticalsAnalyst Views on the Upside Potential of Alnylam Pharmaceuticals
finance.yahoo.com - May 24 at 5:09 PM
Why Alnylam’s Clinical Pipeline Seems PromisingWhy Alnylam’s Clinical Pipeline Seems Promising
finance.yahoo.com - May 24 at 5:09 PM
Alnylam Pharmaceuticals: Banking on Strategic CollaborationsAlnylam Pharmaceuticals: Banking on Strategic Collaborations
finance.yahoo.com - May 24 at 5:09 PM
Exploring Alnylam Pharmaceuticals’ Clinical ProgramsExploring Alnylam Pharmaceuticals’ Clinical Programs
finance.yahoo.com - May 24 at 5:09 PM
What Do Alnylam’s Valuations Indicate?What Do Alnylam’s Valuations Indicate?
finance.yahoo.com - May 24 at 5:09 PM
How Has Alnylam Pharmaceuticals Performed Financially?How Has Alnylam Pharmaceuticals Performed Financially?
finance.yahoo.com - May 24 at 5:09 PM
BRIEF-Alnylam Appoints Colleen Reitan To The Board Of DirectorsBRIEF-Alnylam Appoints Colleen Reitan To The Board Of Directors
www.reuters.com - May 17 at 5:35 PM
BRIEF-Alnylam Pharmaceuticals Says On May 12, Cos Board Expanded Size Of Board From Ten To ElevenBRIEF-Alnylam Pharmaceuticals Says On May 12, Co's Board Expanded Size Of Board From Ten To Eleven
www.reuters.com - May 17 at 8:58 AM
Alnylam Pharma (ALNY) Names Colleen Reitan to BoardAlnylam Pharma (ALNY) Names Colleen Reitan to Board
www.streetinsider.com - May 17 at 8:58 AM
Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?
finance.yahoo.com - May 17 at 8:58 AM
Alnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Quarterly Sales of $19.93 MillionAlnylam Pharmaceuticals, Inc. (ALNY) Expected to Post Quarterly Sales of $19.93 Million
www.americanbankingnews.com - May 17 at 2:18 AM
Zacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) to Announce -$1.53 EPSZacks: Brokerages Anticipate Alnylam Pharmaceuticals, Inc. (ALNY) to Announce -$1.53 EPS
www.americanbankingnews.com - May 15 at 7:10 PM
Alnylam Appoints Colleen Reitan to the Board of DirectorsAlnylam Appoints Colleen Reitan to the Board of Directors
finance.yahoo.com - May 15 at 9:07 AM
Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate UpdateDicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update
www.bizjournals.com - May 14 at 5:00 PM
Huntingtons Disease Therapeutics Market to Grow Owing to Introduction Of Innovative Drugs: Radiant Insights, Inc.Huntington's Disease Therapeutics Market to Grow Owing to Introduction Of Innovative Drugs: Radiant Insights, Inc.
www.prnewswire.com - May 14 at 9:11 AM
Zacks Investment Research Downgrades Alnylam Pharmaceuticals (ALNY) to HoldZacks Investment Research Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
www.americanbankingnews.com - May 10 at 8:13 PM
Alnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by AnalystsAlnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 10 at 3:35 PM
B. Riley Weighs in on Alnylam Pharmaceuticals, Inc.s FY2018 Earnings (ALNY)B. Riley Weighs in on Alnylam Pharmaceuticals, Inc.'s FY2018 Earnings (ALNY)
www.americanbankingnews.com - May 10 at 8:41 AM
FY2022 Earnings Estimate for Alnylam Pharmaceuticals, Inc. (ALNY) Issued By B. RileyFY2022 Earnings Estimate for Alnylam Pharmaceuticals, Inc. (ALNY) Issued By B. Riley
www.americanbankingnews.com - May 9 at 9:47 AM
Alnylam Looks ForwardAlnylam Looks Forward
finance.yahoo.com - May 8 at 5:06 PM
Alnylam Pharmaceuticals (ALNY) Upgraded at Zacks Investment ResearchAlnylam Pharmaceuticals (ALNY) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 8 at 3:33 PM
Alnylam Gets A Shortcut For Lumasiran... This News Is Highly WelcomeAlnylam Gets A Shortcut For Lumasiran... This News Is Highly Welcome
seekingalpha.com - May 8 at 8:48 AM
Alnylam Pharmaceuticals (ALNY) PT Lowered to $107.00Alnylam Pharmaceuticals (ALNY) PT Lowered to $107.00
www.americanbankingnews.com - May 7 at 3:17 PM
Todays Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam PharmaceuticalsToday's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals
finance.yahoo.com - May 7 at 8:46 AM
3 Things In Biotech, May 4: Mercks New Combo, Alnylam Jump Starts, Ocata Gone Forever?3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?
seekingalpha.com - May 5 at 8:59 AM
Alnylam Pharmaceuticals (ALNY) Given New $95.00 Price Target at Stifel NicolausAlnylam Pharmaceuticals (ALNY) Given New $95.00 Price Target at Stifel Nicolaus
www.americanbankingnews.com - May 4 at 7:03 PM
BMO Capital Markets Cuts Alnylam Pharmaceuticals (ALNY) Price Target to $134.00BMO Capital Markets Cuts Alnylam Pharmaceuticals (ALNY) Price Target to $134.00
www.americanbankingnews.com - May 4 at 5:25 PM
Alnylams (ALNY) Q1 Loss Wider than Expected, Sales MissAlnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
www.msn.com - May 4 at 4:59 PM
BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41BRIEF-Alnylam Pharmaceuticals Reports Q1 Loss Per Share Of $1.41
www.reuters.com - May 4 at 4:59 PM
Edited Transcript of ALNY earnings conference call or presentation 3-May-18 8:30pm GMTEdited Transcript of ALNY earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 4:59 PM
Alnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call TranscriptAlnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:47 AM
Alnylam Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call SlidesAlnylam Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 8:47 AM
Alnylam: 1Q Earnings SnapshotAlnylam: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 8:47 AM
Alnylam Pharmaceuticals (ALNY) Lifted to "Strong-Buy" at ValuEngineAlnylam Pharmaceuticals (ALNY) Lifted to "Strong-Buy" at ValuEngine
www.americanbankingnews.com - May 4 at 12:54 AM
Alnylam Pharmaceuticals (ALNY) Posts  Earnings Results, Misses Estimates By $0.07 EPSAlnylam Pharmaceuticals (ALNY) Posts Earnings Results, Misses Estimates By $0.07 EPS
www.americanbankingnews.com - May 3 at 9:38 PM
Alnylam Pharma (ALNY) Announces Alignment with FDA on Accelerated Development Path for Lumasiran for Primary Hyperoxaluria Type 1Alnylam Pharma (ALNY) Announces Alignment with FDA on Accelerated Development Path for Lumasiran for Primary Hyperoxaluria Type 1
www.streetinsider.com - May 3 at 4:58 PM
Alnylam Q1 collaboration revenue up 15%; cash balance $1.6BAlnylam Q1 collaboration revenue up 15%; cash balance $1.6B
seekingalpha.com - May 3 at 4:58 PM
Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period ActivityAlnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
finance.yahoo.com - May 3 at 4:58 PM
Alnylam Reports Alignment With FDA On Accelerated Development Path For LumasiranAlnylam Reports Alignment With FDA On Accelerated Development Path For Lumasiran
www.nasdaq.com - May 3 at 8:44 AM
BRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For LumasiranBRIEF-Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran
www.reuters.com - May 3 at 8:44 AM
Alnylam on go with late-stage study of lumasiran in PH1Alnylam on go with late-stage study of lumasiran in PH1
seekingalpha.com - May 3 at 8:44 AM
Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)Alnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
finance.yahoo.com - May 3 at 8:44 AM
Alnylam to Webcast Presentations at Upcoming May Investor ConferencesAlnylam to Webcast Presentations at Upcoming May Investor Conferences
finance.yahoo.com - May 1 at 4:54 PM
$35.98 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter$35.98 Million in Sales Expected for Alnylam Pharmaceuticals, Inc. (ALNY) This Quarter
www.americanbankingnews.com - April 30 at 4:50 AM
 Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Earnings of -$1.18 Per Share Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Earnings of -$1.18 Per Share
www.americanbankingnews.com - April 28 at 7:22 AM
Alnylam to Webcast Conference Call Discussing First Quarter 2018 Financial ResultsAlnylam to Webcast Conference Call Discussing First Quarter 2018 Financial Results
finance.yahoo.com - April 26 at 4:57 PM
Alnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on ThursdayAlnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:20 AM
Dicerna Pharmaceuticals Settles All Litigation with AlnylamDicerna Pharmaceuticals Settles All Litigation with Alnylam
finance.yahoo.com - April 25 at 5:08 PM
Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of ...Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of ...
www.businesswire.com - April 25 at 8:48 AM
Alnylam Pharmaceuticals: Hitting The Next Growth CurveAlnylam Pharmaceuticals: Hitting The Next Growth Curve
seekingalpha.com - April 25 at 8:48 AM

SEC Filings

Alnylam Pharmaceuticals (NASDAQ:ALNY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alnylam Pharmaceuticals (NASDAQ:ALNY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alnylam Pharmaceuticals (NASDAQ ALNY) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.